Myriad Genetics completes sale of EndoPredict Business to Eurobio Scientific
Myriad Genetics completes sale of EndoPredict Business to Eurobio Scientific
Myriad Genetics to acquire certain assets from Intermountain Precision Genomics
684.83MUSD
See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US62855J1043
CUSIP
62855J104
Sector
Healthcare
Industry
Diagnostics & Research
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
1.40
Book Value
7.68
Dividend Share
-
Dividend Yield
-
Earnings Share
-1.41
Wall Street Target Price
15.82
EPS Estimate Current Year
0.08
EPS Estimate Next Year
0.26
EPS Estimate Current Quarter
0.0303
EPS Estimate Next Quarter
-0.0202
Most Recent Quarter
-
Revenue TTM
837,600,000
Gross Profit TTM
585,400,000
EBITDA
-26,800,000
Profit Margin
-15.20%
Return On Assets TTM
-5.06%
Return On Equity TTM
-17.15%
Revenue Per Share TTM
9.245
Qtly Revenue Growth YOY
7.10%
Diluted Eps TTM
-1.41
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
93
Price Sales TTM
0.811
Price Book MRQ
0.9584
Enterprise Value Revenue
0
Enterprise Value EBITDA
-23
7.60
2.70%68.90
1.85%692.00
1.21%197.84
0.72%1061.79
-1.19%437.75
-0.70%106.28
-0.68%424.24
-0.55%154.00
-0.29%150.28
-0.23%